Imagine leaving your front door unlocked for thirty years, then acting surprised when someone walks in and empties every drawer in the house. That’s essentially what Washington did with one of the most important drug discount programs in American healthcare — and the people who got robbed were the patients it was supposed to protect.
America’s healthcare system is broken. Democrats want to drag us toward the Canadian and European models — the same systems where patients wait months for basic procedures and bureaucrats decide who gets treated. Obamacare didn’t fix hospital profiteering or the insurance racket. It just piled more bureaucracy onto a system already suffocating under it.
Meanwhile, a program called 340B quietly ballooned into a monster.
A lifeline turned cash machine
The 340B Drug Pricing Program was created with a noble purpose: help hospitals serving low-income patients afford expensive medications. Stretch scarce resources. Get drugs to the people who need them most.
What it became was something else entirely. Today, 340B accounts for roughly $100 billion in discounted drug purchases annually. Sprawling academic medical centers and billion-dollar hospital systems — backed by small nations’ worth of lobbyists — turned the program into their private ATM. They buy drugs at steep discounts, collect full Medicare reimbursements, and pocket the difference.
How bad is it? A CMS survey found that seniors’ out-of-pocket cost-sharing was sometimes higher than what hospitals actually paid for the drugs. Let that sink in. Grandma pays more at the pharmacy counter than the hospital paid for her medication — and the hospital keeps the spread.
Then there’s the outright theft. Federal prosecutors convicted a Haitian national in Florida who exploited 340B to the tune of $58 million — bankrolling a mansion near Miami, a fleet of luxury cars, and a stack of investment properties. All from a program meant to help sick, vulnerable Americans.
So who’s actually going to fix this?
Trump steps in where others wouldn’t
This week, the Trump administration unveiled a pilot program replacing automatic upfront drug discounts for hospitals with a rebate model. Translation: discounts get verified before the money changes hands. Novel concept for Washington.
From CMS Administrator Dr. Mehmet Oz:
“This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors.” Medicare officials added that the rule would ensure federal dollars are directed toward clinically appropriate care — not hospital profit margins.
The broader proposed rule goes further, slashing Medicare reimbursement for 340B drugs to the average sales price minus 33.4%. That’s projected to save $5.7 billion in 2027 alone — including $1.15 billion directly from reduced beneficiary drug costs.
The hospital lobby, predictably, is howling. America’s Essential Hospitals accused CMS of taking “an axe” to their funding. Please. When your revenue model depends on overcharging Medicare while vulnerable patients get squeezed, you don’t get to play victim.
This is what real reform looks like
I’ll be honest — I’m worn out by politicians who grandstand about healthcare costs and never lay a finger on the institutions profiting from the chaos. Trump tried this once before in his first term. Got blocked on procedural grounds by the Supreme Court. So he came back prepared — CMS conducted the acquisition cost survey the courts demanded. No shortcuts. No excuses.
The principle here is older than any government program: verify before you pay. Every family in America balances a checkbook that way. Washington should be no different.
Critics will say Trump has no new ideas for healthcare. This proposal says otherwise. The only people furious about this reform are the ones who were cashing in on a broken system — and that tells you everything you need to know.
Key Takeaways
- Trump’s rebate model demands proof before taxpayer drug discounts are paid out.
- The 340B program swelled to $100 billion with virtually zero accountability.
- Seniors sometimes pay more for drugs than hospitals do — and hospitals pocket the difference.
- Projected savings: $5.7 billion in the first year alone.
Sources: Breitbart, Healthcare Dive
